[go: up one dir, main page]

MX2021011389A - Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos. - Google Patents

Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.

Info

Publication number
MX2021011389A
MX2021011389A MX2021011389A MX2021011389A MX2021011389A MX 2021011389 A MX2021011389 A MX 2021011389A MX 2021011389 A MX2021011389 A MX 2021011389A MX 2021011389 A MX2021011389 A MX 2021011389A MX 2021011389 A MX2021011389 A MX 2021011389A
Authority
MX
Mexico
Prior art keywords
imidazolonylquinoline
compounds
therapeutic uses
methoxy
compound
Prior art date
Application number
MX2021011389A
Other languages
English (en)
Inventor
Thomas Fuchss
Axel Becker
Holger Kubas
Ulrich Graedler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021011389A publication Critical patent/MX2021011389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a atropisómeros, formas sólidas, formas de sal y derivados deuterados del inhibidor de ATM 8-(1,3-dimetil-1H-pirazol-4-il)-1-(3-fluoro-5-metoxi-piridin-4-il )-7-metoxi-3-metil-1,3-dihidroimidazo[4,5-c]quinolin-2-ona así como sus composiciones. Los atropisómeros estables no se interconvierten y están representados por las siguientes fórmulas: (ver Fórmulas). Compuesto 1 Compuesto 2.
MX2021011389A 2019-03-27 2020-03-25 Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos. MX2021011389A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19165664 2019-03-27
PCT/EP2020/058425 WO2020193660A1 (en) 2019-03-27 2020-03-25 Imidazolonylquinoline compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2021011389A true MX2021011389A (es) 2021-10-13

Family

ID=65995619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011389A MX2021011389A (es) 2019-03-27 2020-03-25 Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.

Country Status (23)

Country Link
US (1) US20220144828A1 (es)
EP (1) EP3947375B1 (es)
JP (1) JP2022526926A (es)
KR (1) KR20210143263A (es)
CN (2) CN113614083B (es)
AU (1) AU2020247451A1 (es)
BR (1) BR112021018950A2 (es)
CA (1) CA3134874A1 (es)
DK (1) DK3947375T3 (es)
ES (1) ES2984074T3 (es)
FI (1) FI3947375T3 (es)
HR (1) HRP20240650T1 (es)
HU (1) HUE066895T2 (es)
IL (1) IL286079A (es)
LT (1) LT3947375T (es)
MX (1) MX2021011389A (es)
PL (1) PL3947375T3 (es)
PT (1) PT3947375T (es)
RS (1) RS65518B1 (es)
SG (1) SG11202110480YA (es)
SI (1) SI3947375T1 (es)
WO (1) WO2020193660A1 (es)
ZA (1) ZA202108263B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230330027A1 (en) * 2020-09-18 2023-10-19 Merck Patent Gmbh Pharmaceutical preparation
CA3233166A1 (en) * 2021-10-06 2023-04-13 Michal ACHMATOWICZ Methods for separation of enantiomers
KR20230059262A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 이차전지의 저전압 불량 판정 시스템 및 이를 이용한 이차전지의 불량 판정 방법
CN115716829B (zh) * 2022-11-13 2024-05-31 药康众拓(江苏)医药科技有限公司 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112015006398B4 (de) 2015-03-31 2023-07-20 Nec Corporation Verfahren und System zur Beobachtung eines vorgegebenen Überwachungsbereichs
ES2946507T3 (es) * 2015-04-02 2023-07-20 Merck Patent Gmbh Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
CN108752336B (zh) * 2018-05-10 2021-06-04 常州润诺生物科技有限公司 咪唑并喹啉类衍生物及其用途

Also Published As

Publication number Publication date
HUE066895T2 (hu) 2024-09-28
US20220144828A1 (en) 2022-05-12
CN113614083B (zh) 2024-08-27
CN118878534A (zh) 2024-11-01
HRP20240650T1 (hr) 2024-08-02
CA3134874A1 (en) 2020-10-01
LT3947375T (lt) 2024-06-10
EP3947375B1 (en) 2024-04-03
AU2020247451A1 (en) 2021-11-18
JP2022526926A (ja) 2022-05-27
ZA202108263B (en) 2024-04-24
EP3947375A1 (en) 2022-02-09
IL286079A (en) 2021-10-31
SG11202110480YA (en) 2021-10-28
WO2020193660A1 (en) 2020-10-01
BR112021018950A2 (pt) 2022-01-18
SI3947375T1 (sl) 2024-08-30
DK3947375T3 (da) 2024-05-21
CN113614083A (zh) 2021-11-05
PL3947375T3 (pl) 2024-08-05
PT3947375T (pt) 2024-05-28
FI3947375T3 (fi) 2024-05-30
ES2984074T3 (es) 2024-10-28
RS65518B1 (sr) 2024-06-28
KR20210143263A (ko) 2021-11-26

Similar Documents

Publication Publication Date Title
MX2021011389A (es) Compuestos de imidazolonilquinolina y usos terapeuticos de los mismos.
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
UY37997A (es) Agentes antivirales contra la hepatitis b
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
UY36073A (es) ?2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS?.
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CL2020001817A1 (es) Moduladores del receptor c5a
JOP20200030A1 (ar) مركب خماسي الحلقة
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
MX2023007985A (es) Compuestos de alquinileno sustituidos como agentes anticancerigenos.
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
ECSP22027287A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22027784A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio